Assessment of the efficacy of lisdexamfetamine on fatigue in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled study
- 16 June 2025
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 101, 106589
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Comparative pharmacology and abuse potential of oral dexamphetamine and lisdexamfetamine—A literature reviewHuman Psychopharmacology: Clinical and Experimental, 2024
- The use of modafinil for the treatment of fatigue in multiple sclerosis: A systematic review and meta‐analysis of controlled clinical trialsBrain and Behavior, 2024
- Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder2023
- Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trialThe Lancet Neurology, 2021
- A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapyJournal of Psychopharmacology, 2017
- Fatigue Management in Multiple SclerosisCurrent Treatment Options in Neurology, 2016
- Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: A double blind, placebo-controlled studyPsychiatry Research, 2013
- Fatigue in multiple sclerosis — A brief reviewJournal of the Neurological Sciences, 2012
- Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II studyJournal of Neurology, 2012
- Therapeutics for Multiple Sclerosis SymptomsMount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2011